Healthcare (Prescription Drugs)

SB 552 requires Michigan health insurers to cover non-opioid pain medications prescribed for pain treatment, directly affecting insurers and policyholders. The bill mandates that insurers include such drugs on preferred drug lists within 90 days of FDA approval, prohibits discouraging coverage relative to opioids (e.g., labeling non-opioid drugs as "nonpreferred" when opioids are preferred), and prevents overly restrictive prior authorization for non-opioid options. It does not require insurers to cover specific drugs but ensures equal treatment compared to opioid alternatives in formularies. The law applies to all health insurance policies covering prescription drugs in Michigan.

HB 4878 regulates Michigan's participation in the federal 340B drug pricing program, which allows qualifying hospitals to purchase drugs at discounted prices. The bill requires drug manufacturers to report annual price increases exceeding 15% for drugs costing over $40 per treatment course (Sec. 7), and mandates hospitals using 340B discounts to spend savings on patient services or community health programs (Sec. 11). Hospitals must also report detailed financial data about 340B drug transactions to the state by November 2026 (Sec. 15). These provisions directly affect drug manufacturers, hospitals, and pharmacies participating in the 340B program, aiming to increase transparency and ensure discounts benefit patient care.

SB 397 removes the prior authorization requirement for specific prescription drugs under Michigan's medical assistance program (Medicaid). This directly affects Medicaid beneficiaries and healthcare providers by allowing immediate coverage for designated drugs without waiting for insurer approval. The bill amends state law to automatically cover these medications, eliminating a step that previously delayed access. It applies only to drugs explicitly named in the legislation, streamlining treatment for covered conditions.

SB 403 requires Michigan pharmacists to dispense certain medications used to treat addiction without unnecessary delay. This directly affects pharmacists who handle these medications and patients seeking treatment for substance use disorders. The bill amends Michigan's Pharmacy Act (MCL 333.1101 et seq.) by adding a new provision that eliminates administrative barriers causing delays in providing these critical medications. It establishes a clear requirement for prompt dispensing while maintaining pharmacists' existing professional responsibilities.

HB 5108 modifies Michigan's Public Health Code to expand pharmacists' scope of practice. It adds Section 17744h, allowing pharmacists to prescribe certain medications for minor conditions like strep throat or urinary tract infections without a doctor's referral. The bill also updates existing sections (including 17703, 17707, and 17751) to align with these new prescribing authorities. This directly affects community pharmacists and patients seeking convenient, timely care for common, non-emergency conditions. The changes aim to improve access to basic healthcare services within pharmacy settings.

HB 5204 requires health insurers in Michigan to cover prescription drugs for advanced metastatic cancer without first forcing patients to fail other treatments or prove prior drug failures. It directly affects patients diagnosed with advanced metastatic cancer (cancer that has spread beyond its original site) and their health insurance plans. The law prohibits insurers from imposing conditions like "fail first" requirements or demanding proof of previous drug ineffectiveness before approving coverage for these drugs or related symptoms. This applies to all health insurance policies covering prescription drugs for such cancer cases. The bill defines "advanced metastatic cancer" and "associated conditions" (symptoms or side effects worsening without treatment) to clarify coverage requirements.